

# Jerrold H Levy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8984181/publications.pdf>

Version: 2024-02-01

280  
papers

22,580  
citations

10388

72  
h-index

9342

143  
g-index

282  
all docs

282  
docs citations

282  
times ranked

22712  
citing authors

#	ARTICLE	IF	CITATIONS
1	Platelet Activation and Thrombosis in COVID-19. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 055-061.	2.7	17
2	Viral-Induced Inflammatory Coagulation Disorders: Preparing for Another Epidemic. <i>Thrombosis and Haemostasis</i> , 2022, 122, 008-019.	3.4	11
3	Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Critical Care Medicine</i> , 2022, 50, e80-e86.	0.9	30
4	The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 1-9.	4.9	31
5	Consensus Statement: Hemostasis Trial Outcomes in Cardiac Surgery and Mechanical Support. <i>Annals of Thoracic Surgery</i> , 2022, 113, 1026-1035.	1.3	9
6	Inhaled Pulmonary Vasodilator Therapy in Adult Lung Transplant. <i>JAMA Surgery</i> , 2022, 157, e215856.	4.3	10
7	Interpreting recent clinical studies for COVID-19: A continual process with more new data. <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2022, 41, 101016.	1.4	3
8	Therapeutic strategies in patients with coagulopathy and disseminated intravascular coagulation: awareness of the phase-dependent characteristics. <i>Minerva Medica</i> , 2022, 112, .	0.9	7
9	Nevertheless, the importance of coagulation abnormalities should be emphasized in international sepsis guidelines. <i>Journal of Intensive Care</i> , 2022, 10, 4.	2.9	0
10	Heatstroke-induced coagulopathy: Biomarkers, mechanistic insights, and patient management. <i>EClinicalMedicine</i> , 2022, 44, 101276.	7.1	21
11	Thrombin Generation in Cardiac Versus Noncardiac Surgical Cohorts. <i>Anesthesia and Analgesia</i> , 2022, 134, 606-614.	2.2	1
12	The Predictive Value of the 4Ts and HEP Score at Recommended Cutoffs in Patients With Mechanical Circulatory Support Devices. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, , .	1.3	4
13	Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 249-256.	4.9	28
14	Suppression of Fibrinolysis and Hypercoagulability, Severity of Hypoxemia, and Mortality in COVID-19 Patients: A Retrospective Cohort Study. <i>Anesthesiology</i> , 2022, 137, 67-78.	2.5	8
15	ECMO Outcomes, Transfusions, and Hemostatic Management: Quo Vadis?. <i>Annals of Thoracic Surgery</i> , 2022, , .	1.3	0
16	Management of urgent invasive procedures in patients treated with direct oral anticoagulants: An observational registry analysis. <i>Thrombosis Research</i> , 2022, 216, 106-112.	1.7	2
17	The risk of thromboembolic events with early intravenous 2â€• and 4â€•g bolus dosing of tranexamic acid compared to placebo in patients with severe traumatic bleeding: A secondary analysis of a randomized, doubleâ€•blind, placeboâ€•controlled, singleâ€•center trial. <i>Transfusion</i> , 2022, 62, .	1.6	3
18	How to manage anticoagulation during extracorporeal membrane oxygenation. <i>Intensive Care Medicine</i> , 2022, 48, 1076-1079.	8.2	24

#	ARTICLE	IF	CITATIONS
19	ISTH guidelines for antithrombotic treatment in COVID-19. Journal of Thrombosis and Haemostasis, 2022, 20, 2214-2225.	3.8	100
20	Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery. Annals of Surgery, 2021, 274, e204-e211.	4.2	27
21	Andexanet Alfa Use in Cardiac Surgical Patients: A Xa Inhibitor and Heparin Reversal Agent. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 265-266.	1.3	12
22	Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2021, 19, 297-303.	3.8	27
23	Editorial commentary: Vascular injury in acute infections and COVID-19: everything old is new again. Trends in Cardiovascular Medicine, 2021, 31, 6-7.	4.9	9
24	COVID-19-associated Coagulopathy. Anesthesiology, 2021, 134, 366-369.	2.5	14
25	Recent advances in the research and management of sepsis-associated DIC. International Journal of Hematology, 2021, 113, 24-33.	1.6	46
26	Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?. International Journal of Hematology, 2021, 113, 330-336.	1.6	16
27	Fibrin-modulating nanogels for treatment of disseminated intravascular coagulation. Blood Advances, 2021, 5, 613-627.	5.2	11
28	Managing thrombosis and cardiovascular complications of COVID-19: answering the questions in COVID-19-associated coagulopathy. Expert Review of Respiratory Medicine, 2021, 15, 1003-1011.	2.5	12
29	Commentary: Patient blood management in the era of coronavirus disease 2019 "is anything really different?. JTCVS Open, 2021, 5, 97-98.	0.5	0
30	Key Pathogenic Factors in Coronavirus Disease 2019 "Associated Coagulopathy and Acute Lung Injury Highlighted in a Patient With Copresentation of Acute Myelocytic Leukemia: A Case Report. A&A Practice, 2021, 15, e01432.	0.4	1
31	Viscoelastometric Testing to Assess Hemostasis of COVID-19: A Systematic Review. Journal of Clinical Medicine, 2021, 10, 1740.	2.4	43
32	Cerebrospinal Fluid Proteome Changes in Older Non-Cardiac Surgical Patients with Postoperative Cognitive Dysfunction. Journal of Alzheimer's Disease, 2021, 80, 1281-1297.	2.6	9
33	Recommended primary outcomes for clinical trials evaluating hemostatic blood products and agents in patients with bleeding: Proceedings of a National Heart Lung and Blood Institute and US Department of Defense Consensus Conference. Journal of Trauma and Acute Care Surgery, 2021, 91, S19-S25.	2.1	19
34	Viscoelastic testing to assess the effects of rapid fibrinogen concentrate administration after cardiopulmonary bypass: insights from the REPLACE study. Blood Coagulation and Fibrinolysis, 2021, 32, 359-365.	1.0	0
35	Endothelial Injury in COVID-19 and Acute Infections. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1774-1776.	2.4	17
36	Heated Humidified Breathing Circuit Rewarming in Hypothermic Patients Post-Cardiopulmonary Bypass "Pilot Study. Journal of Cardiothoracic and Vascular Anesthesia, 2021, , .	1.3	0

#	ARTICLE	IF	CITATIONS
37	Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia. Chest, 2021, 159, 2417-2427.	0.8	54
38	Roles of Coagulation Abnormalities and Microthrombosis in Sepsis: Pathophysiology, Diagnosis, and Treatment. Archives of Medical Research, 2021, 52, 788-797.	3.3	32
39	COVID-19: Thrombosis, thromboinflammation, and anticoagulation considerations. International Journal of Laboratory Hematology, 2021, 43, 29-35.	1.3	37
40	Thrombogenicity markers for early diagnosis and prognosis in COVID-19: a change from the current paradigm?. Blood Coagulation and Fibrinolysis, 2021, 32, 544-549.	1.0	11
41	A new SOFA score calculation to improve the predictive performance for mortality in sepsis-associated disseminated intravascular coagulopathy patients. Journal of Critical Care, 2021, 64, 108-113.	2.2	2
42	Heparin Resistance – Clinical Perspectives and Management Strategies. New England Journal of Medicine, 2021, 385, 826-832.	27.0	83
43	Prevention of venous thromboembolism and haemostasis monitoring in patients with COVID-19: Updated proposals (April 2021). Anaesthesia, Critical Care & Pain Medicine, 2021, 40, 100919.	1.4	12
44	Comparison of Fibrin Monomers and D-dimers to predict thrombotic events in critically ill patients with COVID-19 pneumonia: A retrospective study. Thrombosis Research, 2021, 205, 8-10.	1.7	6
45	Pitfalls in Diagnosing Vaccine-Induced Immune Thrombotic Thrombocytopenia. Critical Care Medicine, 2021, Publish Ahead of Print, .	0.9	0
46	Proposal of the Definition for COVID-19-Associated Coagulopathy. Journal of Clinical Medicine, 2021, 10, 191.	2.4	83
47	Newly Developed Recombinant Antithrombin Protects the Endothelial Glycocalyx in an Endotoxin-Induced Rat Model of Sepsis. International Journal of Molecular Sciences, 2021, 22, 176.	4.1	10
48	Coagulopathy and Bleeding Management for Aortic Dissection Surgery. , 2021, , 577-593.		0
49	Can We Use Viscoelastic Testing to Evaluate Microvascular Dysfunction in Acute Myocardial Infarction?. JACC Basic To Translational Science, 2021, 6, 762-764.	4.1	0
50	Management of Chronically Anticoagulated Patients. , 2021, , 663-676.		0
51	Newly Proposed Sepsis-Induced Coagulopathy Precedes International Society on Thrombosis and Haemostasis Overt-Disseminated Intravascular Coagulation and Predicts High Mortality. Journal of Intensive Care Medicine, 2020, 35, 643-649.	2.8	60
52	Using Plasma and Prothrombin Complex Concentrates. Seminars in Thrombosis and Hemostasis, 2020, 46, 032-037.	2.7	9
53	Enhanced Recovery After Cardiac Surgery (ERAS Cardiac) Recommendations: An Important First Step – But There Is Much Work to Be Done. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 39-47.	1.3	61
54	Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. Seminars in Thrombosis and Hemostasis, 2020, 46, 089-095.	2.7	124

#	ARTICLE	IF	CITATIONS
55	Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 2302-2309.e6.	0.8	40
56	Pathophysiological Response to Trauma-Induced Coagulopathy: A Comprehensive Review. <i>Anesthesia and Analgesia</i> , 2020, 130, 654-664.	2.2	49
57	Controlled Multifactorial Coagulopathy: Effects of Dilution, Hypothermia, and Acidosis on Thrombin Generation In Vitro. <i>Anesthesia and Analgesia</i> , 2020, 130, 1063-1076.	2.2	20
58	The authors reply. <i>Critical Care Medicine</i> , 2020, 48, e989-e990.	0.9	0
59	Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3174-3183.	3.8	22
60	ISTH DIC subcommittee communication on anticoagulation in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2138-2144.	3.8	69
61	The authors reply. <i>Critical Care Medicine</i> , 2020, 48, e1160-e1161.	0.9	7
62	The Immunologic Effect of Early Intravenous Two and Four Gram Bolus Dosing of Tranexamic Acid Compared to Placebo in Patients With Severe Traumatic Bleeding (TAMPITI): A Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial. <i>Frontiers in Immunology</i> , 2020, 11, 2085.	4.8	26
63	Cryoprecipitate transfusion in bleeding patients. <i>Canadian Journal of Emergency Medicine</i> , 2020, 22, S4-S11.	1.1	3
64	Underlying disorders of disseminated intravascular coagulation: Communication from the ISTH SSC Subcommittees on Disseminated Intravascular Coagulation and Perioperative and Critical Care Thrombosis and Hemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2400-2407.	3.8	16
65	The coagulopathy, endotheliopathy, and vasculitis of COVID-19. <i>Inflammation Research</i> , 2020, 69, 1181-1189.	4.0	302
66	Coagulopathy of Coronavirus Disease 2019. <i>Critical Care Medicine</i> , 2020, 48, 1358-1364.	0.9	412
67	Race-Related disparities in COVID-19 thrombotic outcomes: Beyond social and economic explanations. <i>EClinicalMedicine</i> , 2020, 29-30, 100647.	7.1	17
68	Coagulation abnormalities and thrombosis in patients with COVID-19. <i>Lancet Haematology</i> , 2020, 7, e438-e440.	4.6	1,186
69	Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1859-1865.	3.8	547
70	COVID-19 and its implications for thrombosis and anticoagulation. <i>Blood</i> , 2020, 135, 2033-2040.	1.4	1,892
71	The Contact Activation System: Problems and Paradoxes for Cardiac Anesthesiologists. <i>Anesthesia and Analgesia</i> , 2020, 131, 152-154.	2.2	0
72	In Response. <i>Anesthesia and Analgesia</i> , 2020, 130, e154-e156.	2.2	0

#	ARTICLE	IF	CITATIONS
73	RE: The prothrombin time ratio is not a more effective marker for evaluating sepsis-induced coagulopathy than fibrin-related markers: Response to the Letter to the Editor by Dr Wada. Journal of Thrombosis and Haemostasis, 2020, 18, 1507-1509.	3.8	1
74	Coagulopathy in COVID-19. Journal of Thrombosis and Haemostasis, 2020, 18, 2103-2109.	3.8	453
75	The unique characteristics of COVID-19 coagulopathy. Critical Care, 2020, 24, 360.	5.8	366
76	Management of oral anticoagulants prior to emergency surgery or with major bleeding: A survey of perioperative practices in North America: Communication from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 562-568.	2.3	19
77	Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. Critical Care, 2020, 24, 364.	5.8	118
78	More on Venous Thrombosis during Spaceflight. New England Journal of Medicine, 2020, 382, 1381-1382.	27.0	4
79	Defining trauma-induced coagulopathy with respect to future implications for patient management: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 740-747.	3.8	56
80	The influence of hyperglycemia on neutrophil extracellular trap formation and endothelial glycocalyx damage in a mouse model of type 2 diabetes. Microcirculation, 2020, 27, e12617.	1.8	26
81	The Developing Balance of Thrombosis and Hemorrhage in Pediatric Surgery: Clinical Implications of Age-Related Changes in Hemostasis. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962092909.	1.7	26
82	Restarting Therapeutic Anticoagulation After Elective Craniotomy for Patients with Chronic Atrial Fibrillation: A Review of the Literature. World Neurosurgery, 2020, 137, 130-136.	1.3	5
83	Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO. Critical Care, 2020, 24, 19.	5.8	124
84	Perioperative Thrombosis and Hemostasis. Seminars in Thrombosis and Hemostasis, 2020, 46, 006-007.	2.7	4
85	Thromboinflammation and the hypercoagulability of COVID-19. Journal of Thrombosis and Haemostasis, 2020, 18, 1559-1561.	3.8	529
86	Sepsis-induced Coagulopathy and Disseminated Intravascular Coagulation. Anesthesiology, 2020, 132, 1238-1245.	2.5	99
87	Patient Blood Management. Anesthesiology, 2020, 133, 212-222.	2.5	62
88	Hypercoagulability and coronavirus disease 2019-associated hypoxemic respiratory failure: Mechanisms and emerging management paradigms. Journal of Trauma and Acute Care Surgery, 2020, 89, e177-e181.	2.1	7
89	Arterial and venous thrombosis complicating coronary artery bypass grafting after use of epoetin alfa-epbx. JTCVS Techniques, 2020, 4, 154-155.	0.4	3
90	Protamine, is something fishy about it? The spectre of anaphylaxis continues. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 487-488.	1.3	7

#	ARTICLE	IF	CITATIONS
91	Thrombomodulin in disseminated intravascular coagulation and other critical conditions—a multi-faceted anticoagulant protein with therapeutic potential. <i>Critical Care</i> , 2019, 23, 280.	5.8	79
92	Ischemic limb necrosis in septic shock: What is the role of high-dose vasopressor therapy?. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1973-1978.	3.8	17
93	Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1989-1994.	3.8	325
94	Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis. <i>Critical Care</i> , 2019, 23, 302.	5.8	22
95	Randomized evaluation of fibrinogen versus placebo in complex cardiovascular surgery: post hoc analysis and interpretation of phase III results. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2019, 28, 566-574.	1.1	13
96	Protamine reversal of heparin: a fishy practice?. <i>Europace</i> , 2019, 21, 840-841.	1.7	1
97	Advance in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. <i>Journal of Clinical Medicine</i> , 2019, 8, 728.	2.4	128
98	Proposal of a two-step process for the diagnosis of sepsis-induced disseminated intravascular coagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1265-1268.	3.8	37
99	Guidelines for Perioperative Care in Cardiac Surgery. <i>JAMA Surgery</i> , 2019, 154, 755.	4.3	593
100	The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases. <i>Thrombosis Research</i> , 2019, 179, 11-14.	1.7	41
101	Effects of blood storage age on immune, coagulation, and nitric oxide parameters in transfused patients undergoing cardiac surgery. <i>Transfusion</i> , 2019, 59, 1209-1222.	1.6	2
102	Usefulness of Measuring Changes in SOFA Score for the Prediction of 28-Day Mortality in Patients With Sepsis-Associated Disseminated Intravascular Coagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961882404.	1.7	24
103	Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis. <i>Vox Sanguinis</i> , 2019, 114, 374-385.	1.5	16
104	Andexanet Alfa Use in Patients Requiring Cardiopulmonary Bypass: Quo Vadis?. <i>A&amp;A Practice</i> , 2019, 13, 477-477.	0.4	9
105	Predicting mortality in patients with disseminated intravascular coagulation after cardiopulmonary bypass surgery by utilizing two scoring systems. <i>Blood Coagulation and Fibrinolysis</i> , 2019, 30, 11-16.	1.0	6
106	Maintaining Hemostatic Balance in Treating Disseminated Intravascular Coagulation. <i>Anesthesiology</i> , 2019, 131, 459-461.	2.5	1
107	Tranexamic Acid for Acute Hemorrhage. <i>Anesthesia and Analgesia</i> , 2019, 129, 1459-1461.	2.2	4
108	Derangement of the endothelial glycocalyx in sepsis. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 283-294.	3.8	196



#	ARTICLE	IF	CITATIONS
109	How to interpret recent restrictive transfusion trials in cardiac surgery: More new data or new more data?. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 1038-1040.	0.8	7
110	Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2019, 17, 415-419.	3.8	50
111	Blood and Coagulation. , 2019, , 837-848.		0
112	Protocolized hemostatic factor use in major thoracic aortic surgery. Journal of Cardiovascular Surgery, 2019, 60, 633-636.	0.6	4
113	Argatroban and Bivalirudin for Perioperative Anticoagulation in Cardiac Surgery. Anesthesiology, 2018, 128, 390-400.	2.5	57
114	Reversal agents for non-vitamin K antagonist oral anticoagulants. Nature Reviews Cardiology, 2018, 15, 273-281.	13.7	116
115	Supplementary fibrinogen in the management of bleeding: re-evaluation of data from clinical trials. British Journal of Anaesthesia, 2018, 120, 407-409.	3.4	3
116	Sepsis-Induced Coagulopathy and Japanese Association for Acute Medicine DIC in Coagulopathic Patients with Decreased Antithrombin and Treated by Antithrombin. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 1020-1026.	1.7	32
117	Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. Journal of Thrombosis and Haemostasis, 2018, 16, 231-241.	3.8	333
118	Antifibrinolytic Therapy and Perioperative Considerations. Anesthesiology, 2018, 128, 657-670.	2.5	103
119	Use of factor concentrates for the management of perioperative bleeding: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2018, 16, 170-174.	3.8	34
120	Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers. Journal of Thrombosis and Haemostasis, 2018, 16, 54-64.	3.8	41
121	Journal-related Activities and Other Special Activities at the 2018 American Society of Anesthesiologists Meeting. Anesthesiology, 2018, 129, 634-643.	2.5	0
122	The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review. International Journal of Emergency Medicine, 2018, 11, 55.	1.6	25
123	Bacterial contamination of platelets for transfusion: strategies for prevention. Critical Care, 2018, 22, 271.	5.8	97
124	Protection of the endothelial glycocalyx by antithrombin in an endotoxin-induced rat model of sepsis. Thrombosis Research, 2018, 171, 1-6.	1.7	39
125	Prediction of Early Death in Patients With Sepsis-Associated Coagulation Disorder Treated With Antithrombin Supplementation. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 145S-149S.	1.7	11
126	Prothrombin Complex Concentrates for Perioperative Vitamin K Antagonist and Non-vitamin K Anticoagulant Reversal. Anesthesiology, 2018, 129, 1171-1184.	2.5	27



#	ARTICLE	IF	CITATIONS
127	Perioperative coagulation management: Evolving strategies. <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2018, 37, 317-318.	1.4	0
128	Sugammadex hypersensitivity and underlying mechanisms: a randomised study of healthy non-anaesthetised volunteers. <i>British Journal of Anaesthesia</i> , 2018, 121, 758-767.	3.4	45
129	Use of factor concentrates for the management of perioperative bleeding: reply. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2113-2115.	3.8	0
130	Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD study. <i>Journal of Medical Economics</i> , 2017, 20, 435-442.	2.1	7
131	The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1317-1321.	3.8	46
132	Adjuncts to Blood Component Therapies for the Treatment of Bleeding in the Intensive Care Unit. <i>Transfusion Medicine Reviews</i> , 2017, 31, 258-263.	2.0	5
133	Adult extracorporeal membrane oxygenation: an international survey of transfusion and anticoagulation techniques. <i>Vox Sanguinis</i> , 2017, 112, 443-452.	1.5	94
134	Technology: Is There Sufficient Evidence to Change Practice in Point-of-Care Management of Coagulopathy?. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2017, 31, 1849-1856.	1.3	11
135	Therapeutic Plasma Transfusion in Bleeding Patients: A Systematic Review. <i>Anesthesia and Analgesia</i> , 2017, 124, 1268-1276.	2.2	25
136	Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. <i>New England Journal of Medicine</i> , 2017, 376, 2032-2042.	27.0	225
137	New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. <i>BMJ Open</i> , 2017, 7, e017046.	1.9	230
138	What is the evidence for platelet transfusion in perioperative settings?. <i>Vox Sanguinis</i> , 2017, 112, 704-712.	1.5	19
139	Precision Correction of Coagulopathy or Prothrombin Complex Concentrates?. <i>Anesthesiology</i> , 2017, 127, 744-746.	2.5	6
140	Idarucizumab for Dabigatran Reversal – Full Cohort Analysis. <i>New England Journal of Medicine</i> , 2017, 377, 431-441.	27.0	858
141	Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting. <i>Anesthesia and Analgesia</i> , 2016, 122, 1287-1300.	2.2	84
142	Perioperative management of the bleeding patient. <i>British Journal of Anaesthesia</i> , 2016, 117, iii18-iii30.	3.4	113
143	Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. <i>Critical Care</i> , 2016, 20, 115.	5.8	40
144	Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures. <i>American Journal of Medicine</i> , 2016, 129, S47-S53.	1.5	17

#	ARTICLE	IF	CITATIONS
145	Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal. <i>Critical Care</i> , 2016, 20, 273.	5.8	19
146	Does moderate hypothermia really carry less bleeding risk than deep hypothermia for circulatory arrest? A propensity-matched comparison in hemiarth replacement. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 152, 1559-1569.e2.	0.8	41
147	Discontinuation and management of direct-acting anticoagulants for emergency procedures. <i>American Journal of Emergency Medicine</i> , 2016, 34, 14-18.	1.6	31
148	When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 623-627.	3.8	285
149	Effect of intravenous lidocaine on the transcerebral inflammatory response during cardiac surgery: a randomized-controlled trial. <i>Canadian Journal of Anaesthesia</i> , 2016, 63, 1223-1232.	1.6	18
150	Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial. <i>American Heart Journal</i> , 2016, 182, 62-71.	2.7	23
151	Antithrombin: anti-inflammatory properties and clinical applications. <i>Thrombosis and Haemostasis</i> , 2016, 115, 712-728.	3.4	138
152	Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy. <i>British Journal of Anaesthesia</i> , 2016, 117, 41-51.	3.4	110
153	3-Factor Prothrombin Complex Concentrates in Infants With Refractory Bleeding After Cardiac Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2016, 30, 1627-1631.	1.3	18
154	Idarucizumab for dabigatran overdose. <i>Clinical Toxicology</i> , 2016, 54, 644-646.	1.9	30
155	Letter to the Editor. <i>Journal of Intensive Care Medicine</i> , 2016, 31, 70-71.	2.8	0
156	Edoxaban in the secondary prevention of VTE. <i>Lancet Haematology</i> , the, 2016, 3, e208-e209.	4.6	0
157	The Judicious Use of Recombinant Factor VIIa. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 125-132.	2.7	28
158	Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. <i>Expert Review of Hematology</i> , 2016, 9, 115-122.	2.2	51
159	Three Factor Prothrombin Complex Concentrates in Cardiac Surgery: A Novel Algorithmic Approach to Perioperative Bleeding. <i>Blood</i> , 2016, 128, 5035-5035.	1.4	2
160	Management of Chronically Anticoagulated Patients. , 2016, , 529-542.		0
161	How I use fibrinogen replacement therapy in acquired bleeding. <i>Blood</i> , 2015, 125, 1387-1393.	1.4	137
162	Prothrombin Complex Concentrates in Trauma and Perioperative Bleeding. <i>Anesthesiology</i> , 2015, 122, 923-931.	2.5	88

#	ARTICLE	IF	CITATIONS
163	Antifibrinolytic Therapy for Cardiac Surgery. <i>Anesthesiology</i> , 2015, 123, 214-221.	2.5	89
164	Factor Concentrates for Perioperative Bleeding. <i>Anesthesia and Analgesia</i> , 2015, 121, 4-5.	2.2	0
165	Editorial Comment. <i>A &amp; A Case Reports</i> , 2015, 4, 125-126.	0.7	0
166	Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. <i>Thrombosis and Haemostasis</i> , 2015, 114, 198-205.	3.4	132
167	Novel oral anticoagulants and reversal agents: Considerations for clinical development. <i>American Heart Journal</i> , 2015, 169, 751-757.	2.7	69
168	Point of Care and Factor Concentrate-Based Coagulation Algorithms. <i>Transfusion Medicine and Hemotherapy</i> , 2015, 42, 115-121.	1.6	36
169	Anticoagulation management associated with extracorporeal circulation. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2015, 29, 189-202.	4.0	31
170	Idarucizumab for Dabigatran Reversal. <i>New England Journal of Medicine</i> , 2015, 373, 511-520.	27.0	1,419
171	Protocol Adherence When Managing Massive Bleeding Following Complex Cardiac Surgery: A Study Design Pilot. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2015, 29, 303-310.	1.3	11
172	Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. <i>Critical Care</i> , 2015, 19, 203.	5.8	77
173	Concentration-Dependent Dual Role of Thrombin in Protection of Cultured Rat Cortical Neurons. <i>Neurochemical Research</i> , 2015, 40, 2220-2229.	3.3	19
174	Prothrombin Complex Concentrates and Cardiac Surgery. <i>Blood</i> , 2015, 126, 4712-4712.	1.4	1
175	Direct Oral Anticoagulants. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1333-1351.	2.9	81
176	In reply. <i>Transfusion</i> , 2014, 54, 1443-1444.	1.6	0
177	Comparison of three- and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1428-1436.	3.8	181
178	Impact of Perioperative Blood Pressure Variability on Health Resource Utilization After Cardiac Surgery: An Analysis of the ECLIPSE Trials. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2014, 28, 579-585.	1.3	12
179	Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. <i>Transfusion</i> , 2014, 54, 1389-1405.	1.6	259
180	Dabigatran-related coagulopathy: when can we assume the effect has "worn off"? <i>American Journal of Emergency Medicine</i> , 2014, 32, 1433-1434.	1.6	1

#	ARTICLE	IF	CITATIONS
181	Novel oral anticoagulation agents: New drugs create new paradigms. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 1802-1803.	0.8	1
182	The Influence of Various Patient Characteristics on D-dimer Concentration in Critically Ill Patients and Its Role as a Prognostic Indicator in the Intensive Care Unit Setting. Clinics in Laboratory Medicine, 2014, 34, 675-686.	1.4	25
183	Anticoagulants. Clinics in Laboratory Medicine, 2014, 34, xiii-xv.	1.4	0
184	New Oral Anticoagulantâ€“Induced Bleeding. Clinics in Laboratory Medicine, 2014, 34, 575-586.	1.4	17
185	Clinical Use of the Activated Partial Thromboplastin Time and Prothrombin Time for Screening. Clinics in Laboratory Medicine, 2014, 34, 453-477.	1.4	96
186	Anticoagulation Strategies for the Management of Postoperative Atrial Fibrillation. Clinics in Laboratory Medicine, 2014, 34, 537-561.	1.4	31
187	Off-Label Use of Recombinant Human Factor VIIa. Annals of Thoracic Surgery, 2014, 98, 393-395.	1.3	6
188	Pharmacology and Safety of New Oral Anticoagulants. Clinics in Laboratory Medicine, 2014, 34, 443-452.	1.4	8
189	Perioperative Management of Patients Receiving New Oral Anticoagulants. Clinics in Laboratory Medicine, 2014, 34, 637-654.	1.4	24
190	Cryoprecipitate therapy. British Journal of Anaesthesia, 2014, 113, 922-934.	3.4	161
191	Safe Application of a Restrictive Transfusion Protocol in Moderate-Risk Patients Undergoing Cardiac Operations. Annals of Thoracic Surgery, 2014, 97, 1630-1635.	1.3	21
192	Editorial Comment. A & A Case Reports, 2014, 2, 95.	0.7	1
193	Role of Coagulation Factor Concentrates for Reversing Dabigatran-related Anticoagulation. Anesthesiology, 2014, 120, 1316-1318.	2.5	4
194	In Reply. Anesthesiology, 2014, 120, 243-243.	2.5	0
195	Post Hoc Analysis of Desirudin Versus Enoxaparin for Thromboprophylaxis in High-Risk Patients Undergoing Elective Hip Replacement Surgery. Blood, 2014, 124, 5086-5086.	1.4	0
196	Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo-controlled, multicenter clinical trial. Journal of Thoracic and Cardiovascular Surgery, 2013, 146, 927-939.	0.8	75
197	Biology of Factor XIII and clinical manifestations of Factor XIII deficiency. Transfusion, 2013, 53, 1120-1131.	1.6	70
198	Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. Journal of Thoracic and Cardiovascular Surgery, 2013, 145, 1077-1082.e4.	0.8	18

#	ARTICLE	IF	CITATIONS
199	Point of Care Devices for Assessing Bleeding and Coagulation in the Trauma Patient. <i>Anesthesiology Clinics</i> , 2013, 31, 55-65.	1.4	35
200	Concepts of blood transfusion in adults. <i>Lancet, The</i> , 2013, 381, 1845-1854.	13.7	213
201	Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting. <i>Anesthesiology</i> , 2013, 118, 1466-1474.	2.5	158
202	Sepsis-Induced Disseminated Intravascular Coagulation, Symmetrical Peripheral Gangrene, and Amputations. <i>Critical Care Medicine</i> , 2013, 41, e290-e291.	0.9	18
203	A Case Series of Recombinant Platelet Factor 4 for Heparin Reversal After Cardiopulmonary Bypass. <i>Anesthesia and Analgesia</i> , 2012, 115, 1273-1278.	2.2	16
204	Fibrinogen and Hemostasis. <i>Anesthesia and Analgesia</i> , 2012, 114, 261-274.	2.2	265
205	Recombinant Activated Factor VII. <i>Anesthesia and Analgesia</i> , 2011, 113, 711-712.	2.2	19
206	Bleeding and management of coagulopathy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 142, 662-667.	0.8	84
207	Etiology and Assessment of Hypercoagulability with Lessons from Heparin-Induced Thrombocytopenia. <i>Anesthesia and Analgesia</i> , 2011, 112, 46-58.	2.2	14
208	VTE Prophylaxis with Desirudin in Patients with Thrombocytopenia: Insights From the DESIRABLE Trial,. <i>Blood</i> , 2011, 118, 3293-3293.	1.4	0
209	Anesthetic concerns for patients with coagulopathy. <i>Current Opinion in Anaesthesiology</i> , 2010, 23, 400-405.	2.0	5
210	Multidisciplinary Approach to the Challenge of Hemostasis. <i>Anesthesia and Analgesia</i> , 2010, 110, 354-364.	2.2	142
211	Hereditary Angioedema. <i>Anesthesia and Analgesia</i> , 2010, 110, 1271-1280.	2.2	39
212	Heparin-induced thrombocytopenia and cardiac surgery. <i>Current Opinion in Anaesthesiology</i> , 2010, 23, 74-79.	2.0	36
213	Anticoagulation management during cardiopulmonary bypass: A survey of 54 North American institutions. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2010, 139, 1665-1666.	0.8	51
214	Safety of Recombinant Activated Factor VII in Randomized Clinical Trials. <i>New England Journal of Medicine</i> , 2010, 363, 1791-1800.	27.0	655
215	Antifibrinolytic therapy: new data and new concepts. <i>Lancet, The</i> , 2010, 376, 3-4.	13.7	107
216	Novel Oral Anticoagulants. <i>Anesthesiology</i> , 2010, 113, 726-745.	2.5	80

#	ARTICLE	IF	CITATIONS
217	Transfusion Requirements and Outcomes In the Cohort of Patients Undergoing Isolated CABG Treated with Prasugrel or Clopidogrel: TRITON-TIMI 38 Data Analysis.. Blood, 2010, 116, 1108-1108.	1.4	1
218	Repletion of factor XIII following cardiopulmonary bypass using a recombinant A-subunit homodimer. Thrombosis and Haemostasis, 2009, 102, 765-771.	3.4	44
219	Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. British Journal of Anaesthesia, 2009, 102, 793-799.	3.4	209
220	Is preoperative fibrinogen predictive for postoperative bleeding after coronary artery bypass grafting surgery?. Transfusion, 2009, 49, 2006-2007.	1.6	23
221	A modified recombinant factorÂVIIa: can we make it work Harder, Better, Faster, Stronger?. Journal of Thrombosis and Haemostasis, 2009, 7, 1514-1516.	3.8	2
222	Blood Coagulation: Hemostasis and Thrombin Regulation. Anesthesia and Analgesia, 2009, 108, 1433-1446.	2.2	281
223	Lack of Clinically Significant Interactions Between the Subcutaneously Administered Direct Thrombin Inhibitor Desirudin and Orally Administered Warfarin Upon the International Normalized Ratio.. Blood, 2009, 114, 3131-3131.	1.4	0
224	Pharmacologic methods to reduce perioperative bleeding. Transfusion, 2008, 48, 31S-38S.	1.6	38
225	Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. Thrombosis Research, 2008, 122, 117-123.	1.7	88
226	Improved Clot Formation by Combined Administration of Activated Factor VII (NovoSevenÂ) and Fibrinogen (HaemocomplettanÂ P). Anesthesia and Analgesia, 2008, 106, 732-738.	2.2	66
227	Perioperative Hemostatic Management of Patients Treated with Vitamin K Antagonists. Anesthesiology, 2008, 109, 918-926.	2.5	143
228	Antithrombin Deficiency Increases Thrombin Activity After Prolonged Cardiopulmonary Bypass. Anesthesia and Analgesia, 2008, 106, 713-718.	2.2	50
229	Low Plasma Fibrinogen Levels with the Clauss Method during Anticoagulation with Bivalirudin. Anesthesiology, 2008, 109, 160-161.	2.5	33
230	Management of surgical hemostasis: systemic agents. Vascular, 2008, 16 Suppl 1, S14-21.	0.9	2
231	Reducing Thrombotic Complications in the Perioperative Setting: An Update on Heparin-Induced Thrombocytopenia. Anesthesia and Analgesia, 2007, 105, 570-582.	2.2	40
232	Clevidipine Effectively and Rapidly Controls Blood Pressure Preoperatively in Cardiac Surgery Patients: The Results of the Randomized, Placebo-Controlled Efficacy Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery-1. Anesthesia and Analgesia, 2007, 105, 918-925.	2.2	103
233	Heparin resistance and the potential impact on maintenance of therapeutic coagulation. European Journal of Anaesthesiology, 2007, 24, 37.	1.7	8
234	Regulation of Thrombin ActivityâPharmacologic and Structural Aspects. Hematology/Oncology Clinics of North America, 2007, 21, 33-50.	2.2	21

#	ARTICLE	IF	CITATIONS
235	Anti-inflammatory Strategies and Hemostatic Agents: Old Drugs, New Ideas. Hematology/Oncology Clinics of North America, 2007, 21, 89-101.	2.2	12
236	Heparin-induced Thrombocytopenia, a Prothrombotic Disease. Hematology/Oncology Clinics of North America, 2007, 21, 65-88.	2.2	43
237	The anticoagulated patient: Strategies for effective blood loss management. Surgery, 2007, 142, S71-S77.	1.9	11
238	The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opinion on Investigational Drugs, 2006, 15, 1077-1090.	4.1	81
239	Massive Transfusion Coagulopathy. Seminars in Hematology, 2006, 43, S59-S63.	3.4	82
240	Should aprotinin continue to be used during cardiac surgery?. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 360-361.	3.3	9
241	Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion, 2006, 46, 919-933.	1.6	98
242	Aprotinin is useful as a hemostatic agent in cardiopulmonary surgery: yes. Journal of Thrombosis and Haemostasis, 2006, 4, 1875-1878.	3.8	11
243	A Phase III, Double-blind, Placebo-controlled, Multicenter Study on the Efficacy of Recombinant Human Antithrombin in Heparin-resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass. Anesthesiology, 2005, 102, 276-284.	2.5	129
244	Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery, 2005, 130, 107-113.	0.8	121
245	Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan. Thrombosis and Haemostasis, 2005, 94, 808-13.	3.4	9
246	Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation. American Journal of Health-System Pharmacy, 2005, 62, S15-S19.	1.0	12
247	Management of systemic and pulmonary hypertension. Texas Heart Institute Journal, 2005, 32, 467-71.	0.3	15
248	Evaluation and management of bleeding during cardiac surgery. Psychophysiology, 2005, 4, 368-72.	1.1	24
249	Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion, 2004, 44, 1143-1148.	1.6	276
250	Hemostatic agents. Transfusion, 2004, 44, 58S-62S.	1.6	31
251	Safety of aprotinin in heparinized and nonheparinized patients. Journal of Cardiothoracic and Vascular Anesthesia, 2004, 18, S38-S42.	1.3	10
252	Anaphylactic Reactions to Neuromuscular Blocking Drugs: Are We Making the Correct Diagnosis?. Anesthesia and Analgesia, 2004, 98, 881-883.	2.2	15



#	ARTICLE	IF	CITATIONS
253	Aprotinin: A Pharmacologic Overview. Orthopedics, 2004, 27, s653-8.	1.1	29
254	Efficacy and Safety of Aprotinin in Cardiac Surgery. Orthopedics, 2004, 27, s659-62.	1.1	20
255	The use of haemoglobin glutamer-250 (HBOC-201) as an oxygen bridge in patients with acute anaemia associated with surgical blood loss. Expert Opinion on Biological Therapy, 2003, 3, 509-517.	3.1	26
256	Inflammatory response to cardiopulmonary bypass. Annals of Thoracic Surgery, 2003, 75, S715-S720.	1.3	505
257	Novel pharmacologic approaches to reduce bleeding. Canadian Journal of Anaesthesia, 2003, 50, S26-30.	1.6	5
258	Recombinant Human Transgenic Antithrombin in Cardiac Surgery. Anesthesiology, 2002, 96, 1095-1102.	2.5	57
259	The Plasma Supplemented Modified Activated Clotting Time for Monitoring of Heparinization During Cardiopulmonary Bypass: A Pilot Investigation. Anesthesia and Analgesia, 2002, 95, 26-30.	2.2	39
260	Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: Results of a randomized, double-blind trial. Journal of Thoracic and Cardiovascular Surgery, 2002, 124, 35-42.	0.8	554
261	Pharmacologic preservation of the hemostatic system during cardiac surgery. Annals of Thoracic Surgery, 2001, 72, S1814-S1820.	1.3	107
262	Anaphylaxis. What is monitored to make a diagnosis? How is therapy monitored?. Anesthesiology Clinics, 2001, 19, 705-15.	1.4	2
263	Rapid Evaluation of Coagulopathies After Cardiopulmonary Bypass in Children Using Modified Thromboelastography. Anesthesia and Analgesia, 2000, 90, 1324-1330.	2.2	115
264	The In Vitro Effects of Antithrombin III on the Activated Coagulation Time in Patients on Heparin Therapy. Anesthesia and Analgesia, 2000, 90, 1076-1079.	2.2	61
265	Weal and flare responses to intradermal rocuronium and cisatracurium in humans. British Journal of Anaesthesia, 2000, 85, 844-849.	3.4	80
266	Superoxide Production, Risk Factors, and Endothelium-Dependent Relaxations in Human Internal Mammary Arteries. Circulation, 1999, 99, 53-59.	1.6	98
267	Hemostatic agents and their safety. Journal of Cardiothoracic and Vascular Anesthesia, 1999, 13, 6-11; discussion 36-7.	1.3	14
268	Analyses of coronary graft patency after aprotinin use: Results from the international multicenter aprotinin graft patency experience (IMAGE) trial. Journal of Thoracic and Cardiovascular Surgery, 1998, 116, 716-730.	0.8	246
269	Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion, 1998, 38, 481-498.	1.6	61
270	A Multicenter, Double-Blind, Placebo-Controlled Trial of Aprotinin for Reducing Blood Loss and the Requirement for Donor-Blood Transfusion in Patients Undergoing Repeat Coronary Artery Bypass Grafting. Circulation, 1995, 92, 2236-2244.	1.6	285

#	ARTICLE	IF	CITATIONS
271	Antithrombin deficiency in special clinical syndromes--Part II: cardiovascular surgery. Seminars in Hematology, 1995, 32, 49-55.	3.4	3
272	Pharmacokinetics of Aprotinin in Preoperative Cardiac Surgical Patients. Anesthesiology, 1994, 80, 1013-1018.	2.5	103
273	The ideal agent for perioperative hypertension and potential cytoprotective effects. Acta Anaesthesiologica Scandinavica, 1993, 37, 20-25.	1.6	31
274	New concepts in the treatment of anaphylactoid reactions in anesthesia. Annales Francaises D'Anesthesie Et De Reanimation, 1993, 12, 223-227.	1.4	15
275	Anaphylactic reactions. Canadian Journal of Anaesthesia, 1992, 39, 95-95.	1.6	0
276	Diagnosis and treatment of anaphylactic/anaphylactoid reactions. Monographs in Allergy, 1992, 30, 130-44.	0.2	9
277	Perioperative experience with amrinone. European Journal of Anaesthesiology Supplement, 1992, 5, 15-9.	0.2	2
278	Effects of protamine on histamine release from human lung. Agents and Actions, 1989, 28, 70-72.	0.7	16
279	Evaluation of patients at risk for protamine reactions. Journal of Thoracic and Cardiovascular Surgery, 1989, 98, 200-4.	0.8	17
280	Use of Cardiopulmonary Bypass in Studies of the Circulation. British Journal of Anaesthesia, 1988, 60, 35S-37S.	3.4	16